
Oscar Tahuahua/X
Apr 6, 2025, 13:40
Oscar Tahuahua: Neoadjuvant Aumolertinib in stage III EGFR+ NSCLC
Oscar Tahuahua, Medical Oncology fellow at National Institute of Cancerology, shared a post on X:
“Neoadjuvant Aumolertinib in stage III EGFR+ NSCLC: Ph2 trial
110 mg QD for 16 weeks
ORR: 70.6%
Surgery: 45.1% | R0: 100%
MPR: 21.7% | pCR: 13%
Ex19-Del vs L858R → ORR: 91 vs 59%, MPR: 44 vs 7%
Promising neoadj strategy, esp. in Ex19Del tumors.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 6, 2025, 13:40
Apr 6, 2025, 12:48
Apr 6, 2025, 12:43
Apr 6, 2025, 11:59
Apr 6, 2025, 11:47